BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 17592270)

  • 1. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
    Nonaka D; Henley JD; Chiriboga L; Yee H
    Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma.
    Kim BS; Kim JK; Kang CH; Kim YT; Jung KC; Won JK
    Pathol Res Pract; 2018 Mar; 214(3):343-349. PubMed ID: 29487009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
    Walts AE; Hiroshima K; Marchevsky AM
    Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
    Kuo TT; Chan JK
    Am J Surg Pathol; 1998 Dec; 22(12):1474-81. PubMed ID: 9850173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathologic analysis of 52 cases of thymic epithelial tumor].
    Ma YQ; Miao N; Abulajiang G; Li QX; Liu X; Zhang W; Wang CF; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):249-54. PubMed ID: 20654124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.
    Hayashi A; Fumon T; Miki Y; Sato H; Yoshino T; Takahashi K
    J Clin Exp Hematop; 2013; 53(1):9-19. PubMed ID: 23801129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
    Dorfman DM; Shahsafaei A; Miyauchi A
    Mod Pathol; 1998 Oct; 11(10):989-94. PubMed ID: 9796728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
    Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
    Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases.
    Kriegsmann M; Muley T; Harms A; Tavernar L; Goldmann T; Dienemann H; Herpel E; Warth A
    Diagn Pathol; 2015 Dec; 10():210. PubMed ID: 26643918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of proteasome subunit β5t in thymic epithelial tumors.
    Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
    Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
    Su XY; Wang WY; Li JN; Liao DY; Wu WL; Li GD
    Int J Clin Exp Pathol; 2015; 8(5):5354-62. PubMed ID: 26191237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity.
    Dorfman DM; Shahsafaei A; Chan JK
    Am J Surg Pathol; 1997 Aug; 21(8):936-40. PubMed ID: 9255257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD5 expression in thymic carcinoma.
    Hishima T; Fukayama M; Fujisawa M; Hayashi Y; Arai K; Funata N; Koike M
    Am J Pathol; 1994 Aug; 145(2):268-75. PubMed ID: 7519823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms.
    Pomplun S; Wotherspoon AC; Shah G; Goldstraw P; Ladas G; Nicholson AG
    Histopathology; 2002 Feb; 40(2):152-8. PubMed ID: 11952859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC; Chen PC; Chou TY; Chiang H
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 receptor expression in thymic malignancies.
    Girard N; Teruya-Feldstein J; Payabyab EC; Riely GJ; Rusch VW; Kris MG; Zakowski MF
    J Thorac Oncol; 2010 Sep; 5(9):1439-46. PubMed ID: 20736806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine Differentiation in Thymic Carcinomas: A Diagnostic Pitfall: An Immunohistochemical Analysis of 27 Cases.
    Weissferdt A; Moran CA
    Am J Clin Pathol; 2016 Mar; 145(3):393-400. PubMed ID: 27124922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of gene mutations in KIT-positive thymic epithelial tumors.
    Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
    Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours.
    Pan CC; Chen PC; Wang LS; Lee JY; Chiang H
    Histopathology; 2003 Aug; 43(2):165-72. PubMed ID: 12877732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.
    Khoury T; Chandrasekhar R; Wilding G; Tan D; Cheney RT
    Int J Exp Pathol; 2011 Apr; 92(2):87-96. PubMed ID: 21044186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.